×
About 6,273 results

ALLMedicine™ Familial Hypercholesterolemia Center

Research & Reviews  1,441 results

Cascade screening for familial hypercholesterolemia should be organized at a national l...
https://doi.org/10.1097/MOL.0000000000000832
Current Opinion in Lipidology; Leren TP, Bogsrud MP

Aug 10th, 2022 - Patients with familial hypercholesterolemia (FH) have a markedly increased risk of premature cardiovascular disease. However, there are effective lipid-lowering therapies available to reduce the risk of cardiovascular disease. This makes it import...

Coronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: ...
https://doi.org/10.1161/JAHA.122.025737
Journal of the American Heart Association; Cainzos-Achirica M, Quispe R et. al.

Aug 10th, 2022 - Background The value of coronary artery calcium (CAC) in the allocation of PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitors) among individuals without clinically evident atherosclerotic cardiovascular disease (ASCVD) is unknown for...

Hypertension and clinical outcomes in patients with familial hypercholesterolemia.
https://doi.org/10.1097/HJH.0000000000003204
Journal of Hypertension; Liu MM, Peng J et. al.

Aug 10th, 2022 - Hypertension is a known risk factor for cardiovascular disease; however, its impact on clinical outcomes in patients with heterozygous familial hypercholesterolemia (HeFH) is unclear. Hence, we aimed to investigate the effects of hypertension on s...

Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia:...
https://doi.org/10.1161/JAHA.121.025232
Journal of the American Heart Association; Funabashi S, Kataoka Y et. al.

Aug 6th, 2022 - Background Heterozygous familial hypercholesterolemia (HeFH) more likely exhibits extensive atherosclerotic disease at multiple vascular beds. Lipoprotein(a) (Lp(a)) is an atherogenic lipoprotein that elevates HeFH-related atherosclerotic cardiova...

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT04652726

Aug 5th, 2022 - This is a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemi...

see more →

Guidelines  3 results

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 12th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task ...
https://doi.org/10.1001/jama.2016.9852
JAMA , Bibbins-Domingo K et. al.

Aug 18th, 2016 - Elevations in levels of total, low-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser extent, elevated triglyceride levels are associated with risk of cardiovas...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 18th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

see more →

Drugs  453 results see all →

Clinicaltrials.gov  175 results

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT04652726

Aug 5th, 2022 - This is a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemi...

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers
https://clinicaltrials.gov/ct2/show/NCT00001204

Aug 4th, 2022 - Familial hypercholesterolemia is an autosomal co-dominant disorder resulting in abnormal LDL receptor function, profoundly elevated concentrations of low density lipoproteins, accelerated atherosclerosis and death by early adulthood. This disease ...

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
https://clinicaltrials.gov/ct2/show/NCT05488431

Aug 4th, 2022 - Persons living with HIV infection (PLWH) have a 2-fold higher risk of myocardial infarction and are twice as likely to develop cardiovascular disease accounting for a significant global burden of disease. While the mechanism underlying this excess...

Advanced Lipoproptein Profiling and Cardiovascular Risk Stratification in Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT05066932

Aug 3rd, 2022 - The crucial role of dyslipidaemia, in particular hypercholesterolaemia, in the development of cardiovascular diseases is particularly well documented. The causal role of LDLC in the progression of CVD is indisputable: genetic, epidemiological and ...

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT04659863

Aug 1st, 2022 - This is a two-part (1 year double-blind inclisiran versus placebo/ 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (...

see more →

News  430 results

Early Treatment May Delay Atherosclerosis in Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/969991

Mar 9th, 2022 - Patients with familial hypercholesterolemia (FH) who start lipid-lowering treatment earlier in life may reduce their cardiovascular risk, compared with those who don't begin treatment early, according to results of a recent meta-analysis. They sho...

Early treatment may delay atherosclerosis in familial hypercholesterolemia
https://www.mdedge.com/cardiology/article/252467/cad-atherosclerosis/early-treatment-may-delay-atherosclerosis-familial
Jeff Craven

Mar 7th, 2022 - Patients with familial hypercholesterolemia (FH) who start lipid-lowering treatment earlier in life may reduce their cardiovascular risk, compared with those who don’t begin treatment early, according to results of a recent meta-analysis. They sho.

FDA Approvals, Highlights, and Summaries: Family Medicine
https://www.medscape.com/viewarticle/967605

Feb 17th, 2022 - Cardiology Leqvio (inclisiran) Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisi...

FDA Approvals, Highlights, and Summaries: Health Care Practitioners
https://www.medscape.com/viewarticle/968080

Feb 17th, 2022 - Cardiology Leqvio (inclisiran) Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisi...

Recent Clinical Advances in Reducing Risk for Dyslipidemia
https://www.medscape.com/viewarticle/958749

Feb 15th, 2022 - This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to Medscape InDiscussion. We have two national and world experts with us here today, and I'm excited about our discussion. This morning, we'll start off with a case and th...

see more →

Patient Education  7 results see all →